The ambitious goal of prescribing no antibiotics without a diagnostic by 2030 cannot be achieved by technology alone. It requires a systemic effort involving national action plans and policy reinforcement, driven by partnerships between public entities, private companies, academics, policymakers, and scientists.

The Orphan Drug Act successfully incentivized R&D for rare diseases. A similar policy framework is needed for common, age-related diseases. Despite their massive potential markets, these indications suffer from extremely high failure rates and costs. A new incentive structure could de-risk development and align commercial goals with the enormous societal need for longevity.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

The standard patent system, which rewards innovation through high prices, is inefficient for creating products for the poor like vaccines. Advanced Market Commitments (AMCs) solve this by creating a pull mechanism: a legally binding promise to buy a large quantity at a set price, guaranteeing a market and aligning incentives for innovation.

China's government negotiates lower drug prices but then ensures mass adoption, increasing total revenue for pharmaceutical firms. This "win-win" approach contrasts with Western negotiations that typically reduce firm profits, making China a more attractive market for innovation.

Investors are hesitant to fund antimicrobial resistance research because the field has been stuck for decades trying the same approaches—traditional antibiotics and vaccines—and expecting different results. A fundamental shift in scientific strategy is required to regain investor confidence and make progress against superbugs.

Developing an antibiotic is costly, but its use is short-term and new drugs are held in reserve, making them unprofitable. This market failure, not a lack of scientific capability, has caused pharmaceutical companies to exit the space, creating a worsening global health crisis.

Effective new antibiotics are used sparingly to prevent resistance, which makes them commercially unviable for pharma companies. This "vicious circle" of low usage leading to low revenue actively disincentivizes the development of the very drugs needed to combat superbugs.

The Priority Review Voucher (PRV) program creates a compelling business case for ultra-rare diseases. The voucher, sellable for over $100 million, can provide a significant return to investors on its own. This financial incentive is so strong that a company could theoretically give the resulting drug away for free and still be profitable.